Frazier Life Sciences Management, L.P. Hille Vax, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Hille Vax, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,617,062 shares of HLVX stock, worth $18.7 Million. This represents 9.05% of its overall portfolio holdings.
Number of Shares
10,617,062
Previous 9,781,472
8.54%
Holding current value
$18.7 Million
Previous $163 Million
5.62%
% of portfolio
9.05%
Previous 8.54%
Shares
4 transactions
Others Institutions Holding HLVX
# of Institutions
93Shares Held
40.5MCall Options Held
0Put Options Held
0-
Deerfield Management Company, L.P. (Series C) New York, NY4MShares$7.05 Million1.22% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.48MShares$6.13 Million0.03% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.68 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.99MShares$3.5 Million0.01% of portfolio
-
Abingworth LLP London, X01.84MShares$3.24 Million10.2% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $58.8M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.